This is irrelevant now, but I think the Gates Foundation made a mistake by not partnering with CYDY 2 years ago when the mono data started to come back strong. At that point we were only about 275 million shares fully diluted.
If they had provided $200 million in funding (<1 percent of their assets) , CYDY would have been financially set, and CYDY could have then partnered with them to produce leronlimab profit free for the developing world. Most monoclonal ABs can be produced at <$1 a vial once the manufacturing process is fully developed and at scale. The foundation could have supported this production and wiped out the HIV epidemic--their top concern--and CYDY would be fully funded to pursue its own goals with no further dilution to shareholders (<300 million shares total)
I know the Foundation does not support for profit biotechs, but with certain diseases-especially one so critical to the third world and their mission, they should have been thinking outside the box. Both entities are also based in Washington St., making networking easier.